skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.10e (Release date: 2017-10-30)
SearchBox Top
SearchBox Bottom
Ozarelix (Code C95214)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Ozarelix

Definition: A highly modified, fourth generation linear decapeptide with gonadotropin-releasing hormone (GnRH or LHRH) antagonizing properties. Ozarelix competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with hormonally dependent disease states such as hormone-dependent prostate cancer.

Label: Ozarelix

NCI Thesaurus Code: C95214 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2987000  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
D 63153
D-63 153
LHRH antagonist SPI-153

External Source Codes: 
PDQ Closed Trial Search ID 690937
PDQ Open Trial Search ID 690937 (check for NCI PDQ open clinical trial info)
UMLS CUI C2987000

Other Properties:
     Name Value (qualifiers indented underneath)
code C95214
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom